Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:

Thursday, February 7th, 2008 - 10:20 AM ET:

Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference
Grand Hyatt Hotel

New York City

Monday, February 11, 2008 - 12:30 PM ET:

BIO CEO & Investor Conference

Waldorf=Astoria Hotel

New York City

Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each presentation webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
7. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
8. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
10. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
11. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is ... services. The core expertise of PRC Clinical is focused on Clinical Trial Management, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... is making good progress in evaluating the full range of capabilities of its ... Adult tissue stem cells perform the day-to-day renewal and repair of normal tissues ...
(Date:7/28/2015)... ... ... Xsample 530 sample changer for vials can be used with Anton Paar density meters, ... 12,000 mPas (internal air) up to 36,000 (external air) – and can process up to ... 530 is its removable magazine, which is easily lifted off its hub and carried by ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... Inc (OTC: OMCM.OB) today announced that it ranked number ... 500 of the fastest growing technology, media, telecommunications, life ... are based on the percentage of fiscal year revenue ... percent during this period. OmniComm,s CEO, Cornelis ...
... copper and make way for a better carrier of ... has been in zipping information from one circuit to ... optical signals can carry much more, according to Duke ... demonstrated microscopically small lasers integrated with thin film-light guides ...
... Todd Park, Chief Technology Officer of the U.S. Department of ... Collins, Director of the National Institutes of Health in delivering ... Washington, D.C., on November 8th.   "We look ... of Health and Human Services, the United State,s principal agency ...
Cached Biology Technology:OmniComm Ranks Number 220 on Deloitte's 2010 Technology Fast 500 for Fastest Growing Companies in North America 2OmniComm Ranks Number 220 on Deloitte's 2010 Technology Fast 500 for Fastest Growing Companies in North America 3Light on silicon better than copper? 2Todd Park, Chief Technology Officer of U.S. Department of Health and Human Services, Joins Opening Keynote Line-Up at 2010 mHealth Summit 2Todd Park, Chief Technology Officer of U.S. Department of Health and Human Services, Joins Opening Keynote Line-Up at 2010 mHealth Summit 3
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... N.C. -- As physician-guided robots routinely operate on patients ... eliminate a surprising element from that scenario -- the ... have demonstrated that a robot -- without any human ... in simulated human organs, guide a device to the ...
... responsible for a severe inflammatory disease that has spread ... East to the edge of Europe. University of ... consortium, have revealed some of the genetic mutations that ... in Nature Genetics . Behet,s is a ...
... If mice are administered an antibiotic for three ... appear in the blood and life-threatening disease is averted. ... develop robust, long-term immunity against subsequent infections. This discovery ... Borrmann from the Department of Infectious Diseases at Heidelberg ...
Cached Biology News:Next generation surgical robots: Where's the doctor? 2Next generation surgical robots: Where's the doctor? 3Disease genes that followed the Silk Road identified 2Antibiotics for the prevention of malaria 2Antibiotics for the prevention of malaria 3
Request Info...
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Xcell eukaryotic system, 100 to ... used for electroporation of mammalian ... main unit, CE module for ... square-wave pulses, ShockPod shocking chamber, ...
Request Info...
Biology Products: